Kamada Announces Planned Transition of Chief Financial Officer

Rhea-AI Summary

Kamada (NASDAQ: KMDA) announced that Chief Financial Officer Chaime Orlev will step down from his role effective December 31, 2026 to pursue other opportunities. The company has begun a search for his successor.

Orlev, who has served as CFO since 2017, will provide transitional support to the new appointee. According to Kamada, recent earnings announcements indicate the company is on a growth trajectory with a solid financial position, and leadership emphasized his contributions to Kamada’s growth and operations.

Positive

• Orderly CFO transition with effective date of December 31, 2026 and planned handover support
• Company reports a growth trajectory and solid financial position in recent earnings announcements

Negative

• CFO departure planned for December 31, 2026 after approximately nine years in the role

Market Context

Recent company news produced mixed 24-hour reactions, from +0.57% on a sales agreement to -1.41% aft...

Analysis

Recent company news produced mixed 24-hour reactions, from +0.57% on a sales agreement to -1.41% after FDA approval. That record adds context to this planned CFO transition; the open successor search is the key execution item to watch.

Key Figures

Transition effective date: December 31, 2026 CFO tenure start: 2017 CFO tenure: nine years

3 metrics

Transition effective date December 31, 2026 CFO transition

CFO tenure start 2017 Chaime Orlev served as CFO since 2017

CFO tenure nine years Service period cited in the announcement

Historical Context

5 past events · Latest: Aug 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Earnings scheduling notice	Neutral	-2.2%	Scheduled second-quarter and first-half financial results release for August 12
Jul 20	Sales agreement	Positive	+0.6%	Three-year plasma supply agreement expected to generate approximately $50 million
Jul 13	Clinical data	Positive	+0.7%	CYTOGAM study findings supported potential use in high-risk lung transplant recipients
Jun 01	FDA approval	Positive	-1.4%	FDA approved Kamada's in-house rabies virus neutralization testing laboratory
May 13	Earnings report	Positive	-6.8%	First-quarter revenue and net income increased while annual guidance was reaffirmed

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed positive announcements producing both aligned gains and divergent declines, including a 6.76% decline after positive earnings news.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that Chaime Orlev, its Chief Financial Officer (CFO), will transition out of his role to pursue other opportunities, effective December 31, 2026. Kamada has a search underway to identify a successor to Mr. Orlev, who has served as the Company’s CFO since 2017. Mr. Orlev will provide transitional support to the new CFO to be appointed by Kamada.

“On behalf of the entire Kamada team and the Board of Directors, I would like to thank Chaime for his leadership and significant contributions to Kamada during the past nine years,” said Amir London, Kamada’s Chief Executive Officer. “Chaime has been instrumental in our continued growth while maintaining a strong operating and financial position. I wish him all the best in his future endeavors.”

“I am thankful for the privilege of having served as Kamada’s CFO for the past nine years, including working closely with Amir, our CEO, the rest of Kamada’s management team and its Board of Directors to advance the Company’s growth strategy,” said Chaime Orlev. “As shown by Kamada’s recent earnings announcements, Kamada is on a growth trajectory and has a solid financial position, and I believe this is the right moment to pass the baton and seek new challenges. I look forward to working with the Kamada team and my successor to ensure an efficient and seamless transition.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINROH SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties' pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

FAQ

When is Kamada (NASDAQ: KMDA) CFO Chaime Orlev leaving his role?

Kamada’s CFO, Chaime Orlev, is scheduled to leave his role effective December 31, 2026. According to Kamada, he will continue serving as CFO until then and provide transitional support to the successor once appointed.

Why is Kamada CFO Chaime Orlev transitioning out of his position?

Kamada stated that CFO Chaime Orlev will transition out of his role to pursue other opportunities. According to Kamada, Orlev believes this is the right moment to pass the baton, given the company’s growth trajectory and solid financial position.

How long has Kamada (KMDA) CFO Chaime Orlev served the company?

According to Kamada, CFO Chaime Orlev has served in his current role since 2017 and has been with the company for approximately nine years. The company credits him with contributing to its growth and maintaining a strong operating and financial position.

What transition plans has Kamada announced for its next CFO?

Kamada has started a search to identify a successor for CFO Chaime Orlev. According to Kamada, Orlev will provide transitional support to the new CFO, aiming for an efficient and seamless leadership transition after his planned departure on December 31, 2026.

What does Kamada say about its financial position during this CFO transition?

Kamada reports that, as shown by its recent earnings announcements, it is on a growth trajectory with a solid financial position. According to Kamada, this context supports Orlev’s view that the current period is an appropriate time for a CFO transition.